Table 1.
Relationship between miR-638 expression and clinical characteristics of breast cancer patients
Characteristics | Total number (N=125) |
miR-638 expression
|
P-values | |
---|---|---|---|---|
High (n=55) |
Low (n=70) |
|||
| ||||
Age (years) | 0.363 | |||
<50 | 58 | 23 | 35 | |
≥50 | 67 | 32 | 35 | |
Tumor size (cm) | 0.315 | |||
<2 | 54 | 21 | 33 | |
≥2 | 71 | 34 | 37 | |
ER status | 0.676 | |||
Negative | 61 | 28 | 33 | |
Positive | 64 | 27 | 37 | |
PR status | 0.245 | |||
Negative | 55 | 21 | 34 | |
Positive | 70 | 34 | 36 | |
HER2 status | 0.696 | |||
Negative | 57 | 24 | 33 | |
Positive | 68 | 31 | 37 | |
Lymph node metastasis | 0.015 | |||
Negative | 53 | 30 | 23 | |
Positive | 72 | 25 | 47 | |
TNM stage | 0.021 | |||
I–II | 65 | 35 | 30 | |
III–IV | 60 | 20 | 40 |
Abbreviations: ER, estrogen receptor; PR, progesterone receptor.